Syros Pharmaceuticals, Inc. Syros Pharmaceuticals, Inc.
  • Home
  • Our Coordinated Expression
    • Overview
    • Our Culture, Mission & Values
    • Our Commitment to Diversity, Equity & Inclusion
    • Message from BIO
  • Our People
    • Overview
    • Leadership
    • Board of Directors
    • Founders
  • Programs
    • Overview
    • Tamibarotene
    • SY-2101
    • SY-5609
    • Expanded Access Policy
  • Platform
    • Overview
    • What is Gene Control?
    • Publications and Abstracts
  • Patients
  • Investors & Media
  • Partners
  • Careers
  • Blog
  • Contact
Investors & Media

Investors & Media

  • Overview
  • News
    • Email Alerts
    • Press Releases
  • Events & Presentations
    • IR Calendar
    • Presentations
  • Company Info
    • Profile
    • Leadership
    • Contacts
    • Analyst Coverage
    • FAQ
  • Financial Info
    • Balance Sheet
    • Income Statement
    • Cash Flow
    • Financial Results
    • Annual Reports
    • IRS Tax Form 8937
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • All SEC Filings
    • Annual Filings
    • Quarterly Reports
    • Proxy
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Investor & Media Tools
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed

Press Releases

  • News

  • Email Alerts
  • Press Releases
Jan 26, 2023

Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Higher-Risk Myelodysplastic Syndrome

Jan 9, 2023

Syros Announces Clinical Updates and 2023 Strategic Priorities

Dec 23, 2022

Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 12, 2022

Syros Pharmaceuticals Announces Publication in Blood Advances Demonstrating the Potential of Tamibarotene in Patients with RARA Gene Overexpression, Supporting Ongoing Clinical Development in AML and MDS

Dec 10, 2022

Syros Presents Safety Lead-in Data from SELECT-AML-1 Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine and Announces Plans to Initiate Randomized Portion of Phase 2 Trial

Dec 5, 2022

Syros to Host Virtual Event to Discuss Initial SELECT-AML-1 Data and Unmet Need in Newly Diagnosed Unfit Acute Myeloid Leukemia on December 10

Nov 22, 2022

Syros to Participate at Piper Sandler 34th Annual Healthcare Conference

Nov 14, 2022

Syros Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

Nov 7, 2022

Syros to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022

Nov 4, 2022

Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RSS
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...27
© 2023 Syros Pharmaceuticals, Inc. All Rights Reserved.
Privacy Policy Terms of Use Sitemap
twitter logo linkedin logo